Benefit‐risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation
Kimberly Struble; Kirk Chan‐Tack; Karen Qi; Lisa K. Naeger; Debra Birnkrant
Author Information: Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.